In many major markets, manufacturers rely on detailed guidance to assess design changes — for example, FDA’s well known “When to Submit a 510(k)” decision framework.

India, however, takes a very different approach: the Medical Devices Rules (MDR) 2017 mention change control only briefly, and the Sixth Schedule provides a short list of “major” and “minor” changes.

For companies entering the Indian market, this creates uncertainty — especially when interpreting which design or manufacturing changes must be reported, and how.

This article provides a structured interpretation of the legal text and practical insights for global manufacturers.

 

1. What the Law Says: Major vs. Minor Changes (Sixth Schedule)

 

Major Changes (require prior approval before implementation)

The licence holder must obtain approval from CDSCO or the State Licensing Authority.

If no response is received within 45 days, the change is deemed approved.

Major changes include:

1.         Material of construction

2.         Design changes affecting quality, including specifications, indications for use, performance, or stability

3.         Changes to intended use or indications

4.         Change in sterilization method

5.         Change in approved shelf life

6.         Change in manufacturer name or site (domestic or overseas)

7.         Change in authorised agent (imports)

8.         Label changes, except font size/type/color/design

9.         Manufacturing process, equipment, or testing changes affecting quality

10.       Change in primary packaging material

 

Minor Changes (must be informed within 30 days after implementation)

1.         Design changes not affecting quality, specifications, indications, performance, or stability

2.         Manufacturing process, equipment, or testing changes not affecting quality

3.         Packaging specification changes, except primary packaging

 

2. The Practical Problem: The Law Is Too Short

 

The Sixth Schedule is only a high‑level list.

Two unclear areas often confuse manufacturers:

(A) Minor design changes — must all be reported?

The law states that any design change “not affecting quality” is a minor change and must be informed within 30 days.

In practice, this cannot mean:

•           every drawing update

•           every tolerance refinement

•           every non‑functional cosmetic change

•           every internal software refactoring

•           every supplier‑equivalent component change

If interpreted literally, every engineering iteration would require notification, which is unrealistic and not aligned with risk‑based regulatory practice.

​

(B) Major changes — the list is too broad

The law lists:

•           all material changes

•           all label changes (except font)

•           all manufacturing process changes affecting quality

But in reality:

•           Not all material changes impact biocompatibility

•           Not all label changes impact safety or intended use

•           Not all process changes affect product quality

This is where manufacturers need risk‑based interpretation, similar to FDA, EU MDR, and China NMPA change control principles.

 

3. Our Interpretation: A Risk‑Based Approach for India

 

To avoid unnecessary design freeze or over‑reporting, manufacturers should apply a structured assessment:

Step 1 — Does the change affect:

•           intended use

•           performance

•           safety

•           stability

•           sterilization

•           biocompatibility

•           essential principles

If yes, treat as major change.

Step 2 — Does the change affect quality attributes?

If no, treat as minor change.

Step 3 — Does the change have no regulatory impact?

Examples:

•           internal software code optimization

•           equivalent component replacement

•           non‑functional UI changes

•           documentation-only updates

These should not require reporting, even though the law does not explicitly exempt them.

This aligns India with global practice while staying compliant with the Sixth Schedule.

 

4. Reporting Timelines

 

When you change a medical device that is already approved in India, you must tell the authority.

The rules are simple:

Major changes → Ask for approval before you make the change

You must wait for CDSCO or the State Licensing Authority to review it.

They have 45 days to respond.

If they do not reply within 45 days, the change is automatically approved.

 

Minor changes → Inform the authority after you make the change

You do not need to wait for approval.

You only need to send a notification within 30 days after the change is implemented.

That’s it.

India uses only these two categories — major and minor — and each has a clear reporting timeline.

 

 

5. Outlook: Smarter Change Control for Faster Market Access

India’s MDR 2017 provides only a minimal framework.

Manufacturers who interpret the Sixth Schedule too broadly risk:

•           unnecessary design freeze

•           delayed product improvements

•           long approval timelines

•           inefficient global change management

A risk-based, internationally aligned change assessment helps avoid these pitfalls.

With our support, manufacturers can:

•           evaluate design changes across EU, US, India, China, and IMDRF markets

•           harmonize change control decisions

•           reduce regulatory burden

•           accelerate time‑to‑market

•           maintain full compliance